| PRIMARY INFORMATION |
|---|
| ID | 1324 |
| PMID | 2433236 |
| Year | 1986 |
| Sequence | A-isoGln-A |
| Name | Muramyl tripeptide-phosphatidylethanolamine (MTP-PE, CGP 19835) |
| Length | 3 |
| N-Terminal Modification | muramylNAc=Muramyl-N-Acetyl |
| C-Terminal Modification | PE=phosphatidylethanolamine |
| Linear/ Cyclic | Linear |
| Chirality | L |
| Chemical Modification | isoGln=Isoglutamine |
| Origin of Peptide | A lipophilic derivative of N-acetyl-muramyl-L-alanyl-D-isoglutisoglutamine (MDP) |
| Nature of Peptide/Cargo | MTP-PE is a stimulator of innate immunity and a synthetic molecule derived from muramyl dipeptide (MDP). MTP-PE results from the covalent addition of alanin and dipalmitoyl phosphatidyl ethanolamine to MDP , which is a peptidoglycan found in Gram-positive and Gram-negative bacterial cell walls. |
| Mechanism | Immunomodulators, which are able to modify the host's specific or non-specific defence mechanisms. |
| Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
| Assay | Plaque reduction assay using calf kidney cells |
| Enhancer | Herpes simplex 2/MS viral inoculum logPFU (route)=3.6 (i.vag.) , Minimum effective dose level=1.0mg/kg |
| Properties of enhancer | Not mentioned |
| Concentration | 10 mg/ml sterile MTP-PE incorporated into a gel consisting of 20 g CMC/I dist. water (nine parts) and glycerol (one part). |
| Incubation time | MTP-PE was administered 7 days before infection |
| Tissue permeability (value with units) | Initial symptomatology to Herpes simplex 2/MS is milder, the local disease is significantly mitigated by MTP-PE (P≤ 0.05). Recovery is accelerated and animal becomes asymptomatic by day 15-20. |
| Tissue Sample | Tif:DHP Dunking-Hartley Pirbright guinea pigs. After slight abrasion of the vaginal mucosa, a piece of fibrin foam impregnated with virus suspension was introduced into the vagina. |
| Ex vivo/In vivo/In vitro | in vivo |
| SECONDARY INFORMATION |
|---|
| STRUCTURE | |
| SMILES | N.A. |
